NO333254B1 - Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. - Google Patents
Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.Info
- Publication number
- NO333254B1 NO333254B1 NO20051426A NO20051426A NO333254B1 NO 333254 B1 NO333254 B1 NO 333254B1 NO 20051426 A NO20051426 A NO 20051426A NO 20051426 A NO20051426 A NO 20051426A NO 333254 B1 NO333254 B1 NO 333254B1
- Authority
- NO
- Norway
- Prior art keywords
- clusterin
- melanoma
- composition
- treatment
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40519302P | 2002-08-21 | 2002-08-21 | |
US40815202P | 2002-09-03 | 2002-09-03 | |
US31974802P | 2002-12-02 | 2002-12-02 | |
US47238703P | 2003-05-20 | 2003-05-20 | |
PCT/CA2003/001276 WO2004018675A1 (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20051426L NO20051426L (no) | 2005-05-12 |
NO333254B1 true NO333254B1 (no) | 2013-04-22 |
Family
ID=31950766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051426A NO333254B1 (no) | 2002-08-21 | 2005-03-17 | Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. |
Country Status (16)
Country | Link |
---|---|
US (1) | US7285541B2 (ja) |
EP (1) | EP1530636B1 (ja) |
JP (1) | JP4620585B2 (ja) |
KR (1) | KR101052289B1 (ja) |
AT (1) | ATE478142T1 (ja) |
AU (1) | AU2003258425B2 (ja) |
CA (1) | CA2494764C (ja) |
CY (1) | CY1110936T1 (ja) |
DE (1) | DE60333839D1 (ja) |
DK (1) | DK1530636T3 (ja) |
IL (1) | IL166657A (ja) |
NO (1) | NO333254B1 (ja) |
NZ (1) | NZ538288A (ja) |
PT (1) | PT1530636E (ja) |
SI (1) | SI1530636T1 (ja) |
WO (1) | WO2004018675A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
HU229452B1 (en) | 2002-01-17 | 2013-12-30 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
DK1530636T3 (da) | 2002-08-21 | 2010-11-29 | Univ British Columbia | Behandling af melanomer ved reduktion af clusterinniveauet |
KR101117673B1 (ko) | 2002-08-21 | 2012-03-07 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
CN101389345A (zh) * | 2004-03-19 | 2009-03-18 | 宾州研究基金会 | 治疗黑素瘤的组合方法和组合物 |
WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
AU2005309274B2 (en) * | 2004-11-23 | 2011-07-21 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels |
ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
EP1941040A1 (en) * | 2005-09-19 | 2008-07-09 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation of glucocorticoid receptor expression |
EP2190870A4 (en) * | 2007-08-28 | 2010-12-01 | Auckland Uniservices Ltd | CELL MARKER OF MELANOCYTIC CELL LINE AND USE THEREOF |
ES2734886T3 (es) | 2009-11-24 | 2019-12-12 | Alethia Biotherapeutics Inc | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral |
CA2830195A1 (en) | 2011-03-15 | 2012-09-20 | Martin E. Gleave | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
CN104159611A (zh) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | 共使用簇集蛋白抑制剂和egfr抑制剂以治疗癌症 |
US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
CA2900533A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Anti-clusterin monotherapy for cancer treatment |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
DE69935507T2 (de) * | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6464975B2 (en) | 1998-12-11 | 2002-10-15 | The Research Foundation Of State University Of New York | Compositions and methods for altering cell migration |
US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
EP1242050A4 (en) | 1999-12-21 | 2004-05-26 | Univ Yale | STIMULATION OF ANGIOGEN SE BY THE USE OF SURVIVIN |
US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
HU229452B1 (en) | 2002-01-17 | 2013-12-30 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
KR101117673B1 (ko) * | 2002-08-21 | 2012-03-07 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
DK1530636T3 (da) | 2002-08-21 | 2010-11-29 | Univ British Columbia | Behandling af melanomer ved reduktion af clusterinniveauet |
US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
US8061408B2 (en) | 2009-10-13 | 2011-11-22 | Varel Europe S.A.S. | Casting method for matrix drill bits and reamers |
-
2003
- 2003-08-21 DK DK03792074.1T patent/DK1530636T3/da active
- 2003-08-21 EP EP03792074A patent/EP1530636B1/en not_active Expired - Lifetime
- 2003-08-21 AT AT03792074T patent/ATE478142T1/de active
- 2003-08-21 SI SI200331891T patent/SI1530636T1/sl unknown
- 2003-08-21 AU AU2003258425A patent/AU2003258425B2/en not_active Ceased
- 2003-08-21 US US10/646,391 patent/US7285541B2/en not_active Expired - Fee Related
- 2003-08-21 DE DE60333839T patent/DE60333839D1/de not_active Expired - Lifetime
- 2003-08-21 CA CA2494764A patent/CA2494764C/en not_active Expired - Fee Related
- 2003-08-21 NZ NZ538288A patent/NZ538288A/en not_active IP Right Cessation
- 2003-08-21 WO PCT/CA2003/001276 patent/WO2004018675A1/en active Application Filing
- 2003-08-21 PT PT03792074T patent/PT1530636E/pt unknown
- 2003-08-21 JP JP2005501197A patent/JP4620585B2/ja not_active Expired - Fee Related
- 2003-08-21 KR KR1020057002964A patent/KR101052289B1/ko not_active IP Right Cessation
-
2005
- 2005-02-02 IL IL166657A patent/IL166657A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051426A patent/NO333254B1/no not_active IP Right Cessation
-
2010
- 2010-11-19 CY CY20101101046T patent/CY1110936T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20040082534A1 (en) | 2004-04-29 |
EP1530636A1 (en) | 2005-05-18 |
NO20051426L (no) | 2005-05-12 |
CY1110936T1 (el) | 2015-06-10 |
SI1530636T1 (sl) | 2010-12-31 |
US7285541B2 (en) | 2007-10-23 |
PT1530636E (pt) | 2010-11-17 |
IL166657A0 (en) | 2006-01-15 |
NZ538288A (en) | 2008-04-30 |
AU2003258425B2 (en) | 2008-02-14 |
IL166657A (en) | 2010-05-31 |
DE60333839D1 (de) | 2010-09-30 |
CA2494764A1 (en) | 2004-03-04 |
JP4620585B2 (ja) | 2011-01-26 |
CA2494764C (en) | 2013-04-23 |
DK1530636T3 (da) | 2010-11-29 |
AU2003258425A1 (en) | 2004-03-11 |
EP1530636B1 (en) | 2010-08-18 |
JP2006502243A (ja) | 2006-01-19 |
KR20050058425A (ko) | 2005-06-16 |
WO2004018675A1 (en) | 2004-03-04 |
KR101052289B1 (ko) | 2011-07-27 |
ATE478142T1 (de) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO333254B1 (no) | Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. | |
BRPI0410886A (pt) | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único | |
WO2000049937A3 (en) | Trpm-2 antisense therapy | |
MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
Hwang et al. | A mechanism of low molecular weight fucoidans degraded by enzymatic and acidic hydrolysis for the prevention of UVB damage | |
WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
NZ598778A (en) | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions | |
BRPI0819719B8 (pt) | compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo | |
Yang et al. | The role of CDR1as in proliferation and differentiation of human umbilical cord‐derived mesenchymal stem cells | |
NO20033665L (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
BR0306643A (pt) | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical | |
WO2006013193A8 (en) | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | |
WO2010075287A3 (en) | Compounds and methods for the treatment of pain and other diseases | |
KR102552776B1 (ko) | miRNA를 포함하는 흑색종 전이 억제용 조성물 | |
Park et al. | Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts | |
AU2606000A (en) | Antisense modulation of x-linked inhibitor of apoptosis expression | |
WO2007121054A3 (en) | Nucleic acids for apoptosis of cancer cells | |
DE60126591D1 (de) | In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB | |
WO2005040147A1 (ja) | 抗腫瘍剤 | |
KR20170057194A (ko) | Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물 | |
WO2004043406A3 (en) | ENGINEERED RNAi ADENOVIRUS SILENCING EXPRESSION (ERASE) OF DNA REPAIR PROTEINS | |
TW202434200A (zh) | 用於遞送治療劑至脂肪組織之脂質結合物 | |
BRPI0409980A (pt) | uso de derivados de ácido fenoxiacético para tratar bexiga hiperativa | |
MX2023011909A (es) | Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |